Trial · NCT04737330
Adverse events174
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 174
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Lymphadenopathy | Blood and lymphatic system disorders | Secukinumab 300 mg (Double-blind) | 1 | 14 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Placebo (Double-blind) | 0 | 14 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Any Secukinumab 300 mg (Entire Study) | 1 | 26 | |
| other | Neutropenia | Blood and lymphatic system disorders | Secukinumab 300 mg (Double-blind) | 1 | 14 | |
| other | Neutropenia | Blood and lymphatic system disorders | Placebo (Double-blind) | 0 | 14 | |
| other | Neutropenia | Blood and lymphatic system disorders | Any Secukinumab 300 mg (Entire Study) | 1 | 26 | |
| other | Vertigo | Ear and labyrinth disorders | Secukinumab 300 mg (Double-blind) | 1 | 14 | |
| other | Vertigo | Ear and labyrinth disorders | Placebo (Double-blind) | 0 | 14 | |
| other | Vertigo | Ear and labyrinth disorders | Any Secukinumab 300 mg (Entire Study) | 1 | 26 | |
| other | Thyroid dermatopathy | Endocrine disorders | Secukinumab 300 mg (Double-blind) | 0 | 14 | |
| other | Thyroid dermatopathy | Endocrine disorders | Placebo (Double-blind) | 1 | 14 | |
| other | Thyroid dermatopathy | Endocrine disorders | Any Secukinumab 300 mg (Entire Study) | 1 | 26 | |
| other | Chalazion | Eye disorders | Secukinumab 300 mg (Double-blind) | 0 | 14 | |
| other | Chalazion | Eye disorders | Placebo (Double-blind) | 1 | 14 | |
| other | Chalazion | Eye disorders | Any Secukinumab 300 mg (Entire Study) | 1 | 26 | |
| other | Conjunctival hyperaemia | Eye disorders | Secukinumab 300 mg (Double-blind) | 0 | 14 | |
| other | Conjunctival hyperaemia | Eye disorders | Placebo (Double-blind) | 1 | 14 | |
| other | Conjunctival hyperaemia | Eye disorders | Any Secukinumab 300 mg (Entire Study) | 0 | 26 | |
| other | Conjunctival oedema | Eye disorders | Secukinumab 300 mg (Double-blind) | 0 | 14 | |
| other | Conjunctival oedema | Eye disorders | Placebo (Double-blind) | 1 | 14 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04737330/events